Tempest Therapeutics, Inc.

TPST

US87978U1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
3.47 ^USD	-4.14%		-4.14%	-21.14%

Apr. 09	Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	CI
Apr. 04	Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	CI

Tempest Therapeutics, Inc. announced that it has received $14.996793 million in funding from EcoR1 Capital, LLC, Versant Venture Management, LLC

April 28, 2022

On April 29, 2022, Tempest Therapeutics, Inc. closed the transaction.

Latest news about Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc. Reports New Preclinical Data for TPST-1120 in RCC At the AACR Annual Meeting	Apr. 09	CI
Tempest Therapeutics, Inc. Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications	Apr. 04	CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Scotiabank Initiates Tempest Therapeutics With Sector Outperform Rating, Price Target is $13	Mar. 14	MT
Tempest Therapeutics, Inc. Presents New Data At the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-Tumor Activity of TPST-1120 in Multiple Cancer Types	Mar. 12	CI
North American Morning Briefing : Caution -2-	Nov. 14	DJ
Tempest Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Top Premarket Decliners	23-10-13	MT
Top Premarket Decliners	23-10-12	MT
Health Care Down on Mixed Blessing of Obesity-Drug Promise -- Health Care Roundup	23-10-11	DJ
HC Wainwright Raises Price Target on Tempest Therapeutics to $47 From $35, Maintains Buy Rating	23-10-11	MT
Tempest Therapeutics' TPST-1120 Combination Therapy Delivers Improved Results in Updated Liver Cancer Study; Shares Jump	23-10-11	MT
Tempest Therapeutics, Inc. Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study	23-10-11	CI
Tempest Therapeutics, Inc. Announces Expanded Role for Sam Whiting as Chief Medical Officer and Head of Research and Development	23-09-19	CI
Tempest Therapeutics, Inc. Announces Executive Changes	23-09-07	CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Tempest Therapeutics, Inc. to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers	23-05-25	CI
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Top Midday Gainers	23-04-28	MT
Tempest Therapeutics, Inc. Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma	23-04-28	CI
Tempest Therapeutics, Inc. Announces New Data from its TPST-1120 and TREX1 Programs at 2023 AACR Annual Meeting	23-04-17	CI
Piper Sandler Adjusts Tempest Therapeutics' Price Target to $6 From $10, Keeps Overweight Rating	23-03-23	MT
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Tempest Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-22	CI
Tempest Therapeutics, Inc. to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting	23-03-14	CI

Chart Tempest Therapeutics, Inc.

Duration

Period

More charts

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Companyâs second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.47 USD

Average target price

18.6 USD

Spread / Average Target

+436.02%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TEMPEST THERAPEUTICS, INC.	-21.14%	80.43M
MODERNA, INC.	+22.56%	46.4B
IQVIA HOLDINGS INC.	-1.51%	41.75B
LONZA GROUP AG	+48.83%	41.37B
CELLTRION, INC.	-3.42%	29.71B
ICON PUBLIC LIMITED COMPANY	+10.13%	26.01B
ALNYLAM PHARMACEUTICALS, INC.	-20.44%	19.52B
MEDPACE HOLDINGS, INC.	+26.45%	12.43B
BIO-TECHNE CORPORATION	-0.14%	12.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.47%	12.13B

Other Biotechnology & Medical Research